(Q38042324)

27 August 2017

title

Targeted therapy in rare cancers--adopting the orphans (English)

1 reference

27 August 2017

2

Razelle Kurzrock

1 reference

27 August 2017

Javier Munoz

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

11 September 2012

1 reference

Nature Reviews Clinical Oncology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

631-642

1 reference

Equipoise lost: ethics, costs, and the regulation of cancer clinical research

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Clinical research for rare disease: opportunities, challenges, and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Heterogeneity in cancer guidelines: should we eradicate or tolerate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Networking for rare diseases: a necessity for Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Rare cancers are not so rare: the rare cancer burden in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Prevalence of zebras in general practice: data from the Continuous Morbidity Registration Nijmegen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

How I treat CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): a case study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Myeloma as a model for the process of metastasis: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Advances in therapies for acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Localized mediastinal lymphnode hyperplasia resembling thymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Castleman disease: an update on classification and the spectrum of associated lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Cutaneous castleman's disease responds to anti interleukin-6 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Castleman's disease: from basic mechanisms to molecular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Ewing sarcoma: an eponym window to history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Clinical relevance of molecular genetics to paediatric sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Childhood cancer in Britain: the National Registry of Childhood Tumours and incidence rates 1978-1987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Diabetes and cancer: is diabetes causally related to cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

BRAF mutation status in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Cancer: Melanoma troops massed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Molecular analysis of thyroid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

BRAF inhibition in refractory hairy-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

CD30-targeted antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Brentuximab vedotin for the treatment of CD30+ lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

The challenges of Proteus syndrome: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

A mosaic activating mutation in AKT1 associated with the Proteus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Effectiveness of adaptive designs for phase II cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Anaplastic large-cell lymphoma in women with breast implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Cluster of Hodgkin's lymphoma in residents near a non-operational petroleum refinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

The role of BRAF V600 mutation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Anti-CD30 Antibodies for Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

The occurrence of rare cancers in U.S. adults, 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

What is targeted therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Uncommon tumors and exceptional therapies: paradox or paradigm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B-cell differentiation factor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Radiotherapy in metastatic ewing sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

[Thoracic manifestations of Castleman's disease]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.160

Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes

31 March 2020

1 reference

12 December 2020

Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare

1 reference

12 December 2020

Immunotoxins: a promising treatment modality for metastatic melanoma?

1 reference

12 December 2020

Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.

1 reference

12 December 2020

All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia

1 reference

12 December 2020

Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms

1 reference

12 December 2020

Human herpesvirus 8 encodes a homolog of interleukin-6.

1 reference

12 December 2020

Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA)

1 reference

12 December 2020

10.1038/NRCLINONC.2012.160

Identifiers

DOI

1 reference

27 August 2017

1 reference